PL2167117T3 - Zastosowanie stabilizowanego VWP preparatu FVIII do podawania pozanaczyniowego w terapii i profilaktyce zaburzeń krzepliwości krwi - Google Patents

Zastosowanie stabilizowanego VWP preparatu FVIII do podawania pozanaczyniowego w terapii i profilaktyce zaburzeń krzepliwości krwi

Info

Publication number
PL2167117T3
PL2167117T3 PL08759229T PL08759229T PL2167117T3 PL 2167117 T3 PL2167117 T3 PL 2167117T3 PL 08759229 T PL08759229 T PL 08759229T PL 08759229 T PL08759229 T PL 08759229T PL 2167117 T3 PL2167117 T3 PL 2167117T3
Authority
PL
Poland
Prior art keywords
vwf
therapy
prophylactic treatment
bleeding disorders
extravascular administration
Prior art date
Application number
PL08759229T
Other languages
English (en)
Inventor
Ulrich Kronthaler
Original Assignee
Csl Behring Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Csl Behring Gmbh filed Critical Csl Behring Gmbh
Publication of PL2167117T3 publication Critical patent/PL2167117T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PL08759229T 2007-06-13 2008-06-13 Zastosowanie stabilizowanego VWP preparatu FVIII do podawania pozanaczyniowego w terapii i profilaktyce zaburzeń krzepliwości krwi PL2167117T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07011545 2007-06-13
PCT/EP2008/004770 WO2008151817A1 (en) 2007-06-13 2008-06-13 Use of vwf stabilized fviii preparations and of vwf preparations without fviii for extravascular administration in the therapy and prophylactic treatment of bleeding disorders
EP08759229A EP2167117B1 (en) 2007-06-13 2008-06-13 Use of vwf stabilized fviii preparations for extravascular administration in the therapy and prophylactic treatment of bleeding disorders

Publications (1)

Publication Number Publication Date
PL2167117T3 true PL2167117T3 (pl) 2013-01-31

Family

ID=38219491

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08759229T PL2167117T3 (pl) 2007-06-13 2008-06-13 Zastosowanie stabilizowanego VWP preparatu FVIII do podawania pozanaczyniowego w terapii i profilaktyce zaburzeń krzepliwości krwi

Country Status (10)

Country Link
US (1) US9107902B2 (pl)
EP (2) EP2486936A1 (pl)
JP (1) JP2010529155A (pl)
KR (1) KR20100019999A (pl)
AU (1) AU2008261261B2 (pl)
CA (1) CA2690218C (pl)
DK (1) DK2167117T3 (pl)
ES (1) ES2392569T3 (pl)
PL (1) PL2167117T3 (pl)
WO (1) WO2008151817A1 (pl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
EP2244814B1 (en) 2007-12-28 2021-06-02 Takeda Pharmaceutical Company Limited Recombinant vwf formulations
US8329871B2 (en) * 2008-06-24 2012-12-11 Octapharma Ag Process of purifying coagulation factor VIII
EP2349314B1 (en) 2008-10-21 2013-02-27 Baxter International Inc. Lyophilized recombinant vwf formulations
US8546548B2 (en) 2009-05-27 2013-10-01 Baxter International Inc. Method to produce a highly concentrated immunoglobulin preparation for subcutaneous use
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
JP2019043961A (ja) * 2010-04-20 2019-03-22 オクタファルマ・アーゲー 医薬タンパク質の新規な安定化剤
US8772462B2 (en) 2010-05-26 2014-07-08 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
CN103732244A (zh) * 2011-06-10 2014-04-16 巴克斯特国际公司 通过施用重组vwf治疗凝血疾病
CN102279273A (zh) * 2011-07-19 2011-12-14 苏州大学 一种血管性血友病因子瑞斯托霉素辅因子酶联免疫试剂盒
US20150045303A1 (en) * 2012-04-24 2015-02-12 Novo Nordisk A/S Pharmaceutical Composition Suitable for Treatment of Haemophilia
US20150080309A1 (en) * 2012-04-24 2015-03-19 Nova Nordisk A/S Compounds Suitable for Treatment of Haemophilia
EP2796145B1 (en) 2013-04-22 2017-11-01 CSL Ltd. A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
EA201691111A1 (ru) 2014-01-10 2017-01-30 Байоджен Ма Инк. Химерные белки фактора viii и их применение
BR112016026842A2 (pt) 2014-06-06 2017-12-12 Octapharma Ag preparação compreendendo fator viii e peptídeos de fator de von willebrand
SG11201706659WA (en) * 2015-03-06 2017-09-28 Csl Behring Recombinant Facility Ag Modified von willebrand factor having improved half-life
CA2986626A1 (en) 2015-05-22 2016-12-01 Csl Behring Recombinant Facility Ag Truncated von willebrand factor polypeptides for treating hemophilia
US12171808B2 (en) * 2016-05-20 2024-12-24 Octapharma Ag Glycosylated VWF fusion proteins with improved pharmacokinetics
JP2020504082A (ja) 2016-11-11 2020-02-06 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 血液凝固障害の処置又は予防における血管外投与のための切断型フォン・ヴィルブランド因子ポリペプチド
KR20190090827A (ko) 2016-12-02 2019-08-02 바이오버라티브 테라퓨틱스 인크. 키메라 응고 인자를 사용해 혈우병성 관절증을 치료하는 방법
DK3641800T5 (da) 2017-06-22 2024-08-26 CSL Behring Lengnau AG Modulation af fviii immunogenicitet ved trunkeret vwf
JP7326246B2 (ja) 2017-07-07 2023-08-15 武田薬品工業株式会社 待機手術を受ける、重度のフォンヴィレブランド病を患う患者の、組換えｖｗｆの投与による治療法
FI3648788T5 (fi) 2017-07-07 2024-09-09 Takeda Pharmaceuticals Co Maha-suolikanavan verenvuodon hoito vaikeaa von willebrandin tautia sairastavilla potilailla antamalla rekombinanttia vwf:ää
KR102914074B1 (ko) 2018-05-18 2026-01-16 바이오버라티브 테라퓨틱스 인크. A형 혈우병의 치료 방법
EA202192140A1 (ru) 2019-02-01 2021-12-15 Такеда Фармасьютикал Компани Лимитед СПОСОБЫ ПРОФИЛАКТИЧЕСКОГО ЛЕЧЕНИЯ РЕКОМБИНАНТНЫМ ФВ (рФВ)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4586250A (en) * 1983-10-03 1986-05-06 Westinghouse Electric Corp. Apparatus for sleeving tubes in hostile environments
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
FR2673632A1 (fr) 1991-03-08 1992-09-11 Lille Transfusion Sanguine Procede de preparation de concentre de facteur von willebrand humain de tres haute purete, approprie a un usage therapeutique.
US5179385A (en) 1992-01-02 1993-01-12 International Marine Industries, Inc. Visual navigation aid with point of interest feature
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
IL113010A0 (en) 1994-03-31 1995-10-31 Pharmacia Ab Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
DE4435485C1 (de) 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
ES2237551T3 (es) * 2000-02-08 2005-08-01 Allergan, Inc. Composiciones farmaceuticas que contienen toxina botulinica.
DE10246125A1 (de) 2002-10-01 2004-04-15 Aventis Behring Gmbh Konzentrat eines Faktor VIII:C-haltigen von-Willebrand-Faktors und das dazu gehörige Verfahren
AU2005322067B8 (en) * 2004-12-27 2012-07-26 Takeda Pharmaceutical Company Limited Polymer-von Willebrand factor-conjugates
PE20080610A1 (es) 2006-08-22 2008-07-15 Boehringer Ingelheim Int Nuevos beta-agonistas enantiomericamente puros, procedimientos para su preparacion y uso como medicamentos
MX2009007145A (es) * 2006-12-27 2009-08-27 Nektar Therapeutics Al Corp Conjugados de polimero con factor viii y factor de von willebrand que tienen una ligadura liberable.

Also Published As

Publication number Publication date
EP2486936A1 (en) 2012-08-15
KR20100019999A (ko) 2010-02-19
AU2008261261B2 (en) 2013-06-27
WO2008151817A1 (en) 2008-12-18
ES2392569T3 (es) 2012-12-11
US20100286047A1 (en) 2010-11-11
US9107902B2 (en) 2015-08-18
CA2690218C (en) 2017-02-28
EP2167117A1 (en) 2010-03-31
AU2008261261A1 (en) 2008-12-18
DK2167117T3 (da) 2012-11-19
EP2167117B1 (en) 2012-08-15
CA2690218A1 (en) 2008-12-18
JP2010529155A (ja) 2010-08-26

Similar Documents

Publication Publication Date Title
DK2167117T3 (da) Anvendelse af VWF-stabiliserede FVIII-præparater til ekstravaskulær administration til terapeutisk og profylaktisk behandling af blødningsforstyrrelser
PT2601961T (pt) Composições compreendendo lag-3 e anticorpos terapêuticos e as suas utilizações no tratamento de cancro
IL178775A (en) Pharmaceuticals containing glucocorticoid for use in the treatment of disorders requiring acute glucocorticoid therapy
EP2358378A4 (en) TOPICAL FORMULATION FOR THE TREATMENT OF INFLAMMATORY DISEASE, SKIN AND SLAUGHTER DISEASES AND SIMILAR DISEASES
IL216599A (en) 4,1-Bi-Conjugated Phthalazine History, Pharmaceuticals Containing Them and Their Use in Cancer Treatment
IL209121A (en) Indazolil history, their medicinal preparations and their use in the preparation of medications for the treatment of inflammatory diseases
IL232325A0 (en) 18-methyl-7,6-methylene-3-oxo-17-paragan-4-en-21, 17b-carbolactones, pharmaceutical preparations containing these compounds and their use for the treatment of endometrial disease
IL202840A (en) Preserved pyridinone n-aryl, pharmaceuticals including them and their use in the manufacture of drugs to treat fibrosis-mediated disorders and collagen-mediated disorders
IL228952A0 (en) Pharmaceutical compositions comprising ferric citrate for reducing serum phosphate levels, and use thereof for the preparation of medicaments for treating or ameliorating calcium-associated disorders
IL210545A (en) Transplantation devices for use of octreotide transport and use of octreotide to create drugs
MY173215A (en) Acetylcysteine compositions and methods of use thereof
IL211842A (en) Antibodies or fragments of their human tgfbrii, pharmacological preparations containing them and their use in the preparation of a drug for inhibiting anogenesis
EP1971308A4 (en) TOPICALLY ADMINISTERING VOCTRIC COMPOSITION AND THERAPEUTIC FORMULATIONS COMPRISING THE SAME
EP2079526A4 (en) COMPOSITIONS AND ITS USES IN THE TREATMENT OF WOUNDS
ZA200908928B (en) Formulations for the oral administration of therapeutic agents and related methods
IL212567A (en) Zaxanthin, alone or in combination with rutin, spermidine, or both, for the treatment of scalp disorders, use of zaxanthin, alone or in combination with rutin, spermidine or both, for the preparation of a medicinal or cosmetic or nutritional preparation for the treatment of scalp, and a medicinal, cosmetic or nutritional preparation containing Alone or in a mixture with routine, spermidine, or both
GB2458868B (en) Fluphenazine based combination for use in the treatment of protein aggregation diseases
ZA201001207B (en) Therapeutic formulations for the treatment of cold and flu-like symptoms
IL195155A (en) Dosage form for delayed glucocorticoid release and its use in the treatment of rheumatic diseases
PL2193789T3 (pl) Zastosowanie 5-metylo-1,3-benzenodiolu lub jego pochodnych w przygotowaniu leku i funkcjonalnej żywności do leczenia lub zapobiegania depresji
IL178939A (en) Double and triple combinations suitable for synergistic treatment of breast cancer, including pharmaceuticals and their use in the manufacture of drugs and drugs for the treatment of breast cancer
SI1807156T1 (sl) Nove farmacevtske oblike za uporabo pri zdravljenju nespečnosti
PT1803456E (pt) Composições farmacêuticas que compreendem l-733060 para utilização no tratamento de tumores cancerígenos
GB0710277D0 (en) Use of antivirals in the treatment of medical disorders
IL199966A0 (en) Azabicycloalkane derivatives, preparation thereof and use thereof in therapy